See other companies on Welcome to the Jungle

Enveda Biosciences

Drug discovery & development platform

Enveda Biosciences logo
101-200 employees
  • Healthcare
  • B2B
  • Artificial Intelligence
  • Manufacturing
  • Deep Tech
  • Robotics
  • Machine Learning
Boulder, CO

Company mission

Enveda Biosciences' mission is to deliver hope to every patient.

Top investors

Few candidates hear
back within 2 weeks

33% employee growth in 12 months

Our take

Despite massive innovations in healthcare of late, drug discovery is still an arduous process, and a huge amount of the natural world remains unexplored for medicinal molecules. Enveda Biosciences delivers a platform to rapidly probe for new medically active compounds, creating the world's "most diverse biologically annotated dataset of small molecules".

With Enveda's AI and ML-led technology, the chemical structure and biological activity of molecules can be assessed at speed and scale, using high-throughput experiments to generate the dataset that can be rapidly searched for new leads. This represents a breakthrough compared to the long and slow, classical drug discovery process which involves testing one molecule at a time.

Enveda Biosciences has seen substantial funding that is cited to help progress multiple platform-derived molecules to the clinic, allowing the company to apply its discovery technology to the drug development stages - with targets including inflammation, fibrosis, and neurosensory disorders. With investors including leaders in biotech and technology, it is clear the company is exciting the space and has the potential to make great impact in the future.

Freddie headshot

Freddie

Company Specialist at Welcome to the Jungle

Benefits

  • Flexible work hours and paid parental leave
  • Flexible PTO
  • Company wide weeklong break to recharge

Company values

  • Trustworthy - We're people of integrity, first and always
  • Empowering - We're enabled to do our best work, with autonomy & accountability
  • Collaborative - We work together, at the bench & around the world

Funding (last 2 of 7 rounds)

Nov 2024

$130m

LATE VC

Jun 2024

$55m

SERIES B

Total funding: $351.8m

This company has top investors

Leadership

Spent two years at Recursion Pharmaceuticals, including a year as a Senior Product Manager of Assets and Translation.